D. Western Therapeutics Institute Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Yuichi Hidaka

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	15.9yrs
Propriété du PDG	7.7%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	10.6yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Yuichi Hidaka (51 yo)

15.9yrs

Titularisation

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Yuichi Hidaka	President	15.9yrs	pas de données	7.69% € 1.8m
Sayako Matsubara	CFO & Director	1.7yrs	pas de données	0.015% € 3.4k
Yoshiyuki Yamakawa	Independent Outside Director	14.7yrs	pas de données	0.047% € 10.9k
Eisaku Nakamura	Independent Outside Director	6.6yrs	pas de données	0.00026% € 60.0
Masaaki Suzuki	Member of Scientific Advisory Board	no data	pas de données	pas de données
Tasuku Honjyo	Member of Scientific Advisory Board	no data	pas de données	pas de données
Masato Shibuya	Member of Scientific Advisory Board	no data	pas de données	pas de données
Arata Uemura	Member of Scientific Advisory Board	no data	pas de données	pas de données
Anthony Means	Member of Scientific Advisory Board	no data	pas de données	pas de données
Walter Chazin	Member of Scientific Advisory Board	no data	pas de données	pas de données
Yasuhiko Ito	Member of Scientific Advisory Board	no data	pas de données	pas de données
Yasumi Uchida	Member of Scientific Advisory Board	no data	pas de données	pas de données

10.6yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 6DW est chevronné et expérimenté ( 10.6 années d'ancienneté moyenne).

D. Western Therapeutics Institute Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

Recent updates

D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023)

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023)

New minor risk - Shareholder dilution

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022)

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022)

New minor risk - Share price stability

D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022)

D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Insufficient new directors

Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021)

D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.

D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021

D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020

D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

PDG

Titularisation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen